Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Acta Haematol ; 81(2): 70-4, 1989.
Artigo em Inglês | MEDLINE | ID: mdl-2496553

RESUMO

Twenty patients with severe aplastic anemia (SAA) were treated with low doses (1-5 mg/kg/day) of a high-potency antithymocyte globulin (ATG) produced in Mexico, shown to have at least a 10-fold potency as compared with other globulins of commercial sources. Patients received ATG within a 10-day period, every other day (5 doses) at a dose of 1 mg/kg/day (4 courses), 2 mg/kg/day (12 courses) or 5 mg/kg/day (8 courses). Four patients received 2 consecutive courses of different doses of ATG. A response rate of 42% was recorded in the group, assessed by means of increases in reticulocytes, granulocytes or platelets. One patient showed a complete remission. The 570-day survival of the group was 51%. It is concluded that the domestically produced ATG is useful in the treatment of some patients with SAA in Mexico.


Assuntos
Anemia Aplástica/terapia , Soro Antilinfocitário/administração & dosagem , Adolescente , Adulto , Anemia Aplástica/tratamento farmacológico , Anemia Aplástica/mortalidade , Animais , Soro Antilinfocitário/efeitos adversos , Criança , Pré-Escolar , Esquema de Medicação , Feminino , Cavalos , Humanos , Masculino , Pessoa de Meia-Idade , Prednisona/uso terapêutico , Indução de Remissão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA